Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned

作者：Sunhee Ro, Weidong Zhang, Qi Jiang, Xiaoyun Li, Rong Liu, Chengxing Lu, Olga Marchenko, Linda Sun, Jing Zhao · 发表于：Therapeutic Innovation & Regulatory Science · 年份：2023 · DOI：10.1007/s43441-023-00528-y · 被引用次数：7 · 研究领域：Statistical Methods in Clinical Trials、Health Systems, Economic Evaluations, Quality of Life、Advanced Causal Inference Techniques

Despite increasing utilization of real-world data (RWD)/real-world evidence (RWE) in regulatory submissions, their application to oncology drug approvals has seen limited success. Real-world data is most commonly summarized as a benchmark control for a single arm study or used to augment the concurrent control in a randomized clinical trial (RCT). While there has been substantial research on usage of RWD/RWE, our goal is to provide a comprehensive overview of their use in oncology drug approval submissions to inform future RWD/RWE study design. We will review examples of applications and summarize the strengths and weaknesses of each example identified by regulatory agencies. A few noteworthy case studies will be reviewed in detail. Operational aspects of RWD/RWE study design/analysis will be also discussed.